DZD6008 combination therapy for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination treatment for people with advanced non-small cell lung cancer that has an EGFR mutation. It aims to see if this combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced non-small cell lung cancer that is not squamous and has an EGFR mutation.
- You have either not received any treatment for your cancer yet, or your cancer has progressed after taking a third-generation EGFR TKI.
- You have at least one tumor that can be measured on a scan.
- You have not had treatment for cancer in the past 2 weeks (for most drugs) or 4 weeks (for immunotherapy or antibody drugs).
- You do not have certain heart conditions or other serious illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial studies an oral (by mouth) EGFR-blocking medicine (DZD9008) in people with advanced lung cancer that has EGFR mutations. It’s for cancers that have grown despite standard treatment or couldn’t be tolerated, and aims to control the cancer while keeping side effects manageable.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.